Showing 1-6 of 6 results for "71-00-1"
Elena Toffol et al.
Menopause (New York, N.Y.), 21(5), 493-500 (2013-09-26)
Melatonin synthesis and secretion are partly modulated by estrogen and progesterone. Changes in melatonin concentrations, possibly related to the menopausal transition, may be associated with climacteric mood, sleep, and vasomotor symptoms. The aims of this study were to compare the...
Neil Chester et al.
British journal of clinical pharmacology, 57(1), 62-67 (2003-12-18)
To study the elimination of ephedrines with reference to the International Olympic Committee (IOC) doping control cut-off levels, following multiple dosing of over-the-counter decongestant preparations. A double-blind study was performed in which 16 healthy male volunteers were administered either pseudoephedrine...
Katherine Q Philla et al.
Journal of pediatric endocrinology & metabolism : JPEM, 28(9-10), 1101-1106 (2015-05-30)
The purpose of this study was to examine the effect of chronic swallowed glucocorticoids on adrenal function during the treatment of eosinophilic esophagitis (EoE) in children. Serum cortisol levels were obtained in children with EoE pre- and post-treatment with swallowed...
Angelo Di Leo et al.
The Lancet. Oncology, 12(12), 1134-1142 (2011-09-16)
Prediction of response to anthracycline-based therapy for breast cancer is challenging. We aimed to assess the value of HER2 and TOP2A as predictive markers of response to anthracycline-based adjuvant therapy in patients with early breast cancer. We did a meta-analysis...
Olivier Varenne et al.
Lancet (London, England), 391(10115), 41-50 (2017-11-06)
Elderly patients regularly receive bare-metal stents (BMS) instead of drug-eluting stents (DES) to shorten the duration of double antiplatelet therapy (DAPT). The aim of this study was to compare outcomes between these two types of stents with a short duration...
N Bhala et al.
Lancet (London, England), 382(9894), 769-779 (2013-06-04)
The vascular and gastrointestinal effects of non-steroidal anti-inflammatory drugs (NSAIDs), including selective COX-2 inhibitors (coxibs) and traditional non-steroidal anti-inflammatory drugs (tNSAIDs), are not well characterised, particularly in patients at increased risk of vascular disease. We aimed to provide such information...

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.